Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective study for efficacy of bictegravir/ emtricitabine/tenofovir alafenamide compared to other 3DRs that included boosted darunavir, dolutegravir or elvitegravir/cobicistat in ART-naïve adults with advanced HIV-1 infection

Next Previous
X
Search
Trial Profile

Retrospective study for efficacy of bictegravir/ emtricitabine/tenofovir alafenamide compared to other 3DRs that included boosted darunavir, dolutegravir or elvitegravir/cobicistat in ART-naïve adults with advanced HIV-1 infection

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Cobicistat/elvitegravir; Darunavir; Dolutegravir
  • Indications HIV infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Aug 2022 Results presented at the 24th International AIDS Conference
    • 20 Apr 2021 New trial record
    • 10 Mar 2021 Results presented at the 28th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top